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Tuberculosis (TB) is the commonest cause of morbidity and 
mortality in HIV-infected people in sub-Saharan Africa.1 The 
mortality associated with TB is considerably higher in HIV-
infected than HIV-negative patients.2 Furthermore, TB is a 
more rapidly progressive disease in HIV-infected people.3 This 
means that any delay in the diagnosis of active TB in HIV co-
infected patients is more likely to result in clinical deterioration 
and greater morbidity and mortality.4 The diagnostic window 
of opportunity is therefore narrower. Active TB has been found 
at autopsy in around 50% of AIDS-related deaths in Africa,5,6 
and in almost half the diagnosis was not made ante-mortem.5
This situation is complicated by the fact that TB is more 
difficult to diagnose in HIV-infected patients. HIV modifies 
the clinical presentation of TB, particularly in those with more 
advanced immunosuppression. HIV-infected patients are twice 
as likely to have sputum smear-negative, culture-positive 
pulmonary TB (PTB).7-9 This results from their compromised 
immune response causing less cavity formation.10 The sputum 
smear has traditionally been used as the method for making 
an early diagnosis of PTB. The reduction in sensitivity of this 
test in HIV-infected patients leads to diagnostic delay. Sputum 
culture is a more sensitive method of diagnosing PTB in such 
cases, but can take up to 8 weeks before a result is available. 
The patient’s condition invariably deteriorates during this 
interval. Other factors contributing to diagnostic delay are that 
patients with HIV-associated PTB present more commonly with 
atypical or normal chest radiographs11,12 and extrapulmonary 
tuberculosis (EPTB) is more common in the context of HIV 
infection.13 
This diagnostic delay also results in increased hospitalisation 
and increased costs to the health system. It has also been 
proposed that delay in the initiation of TB treatment may 
accelerate HIV infection.14
It is imperative that efforts be made to expedite the diagnosis 
of TB in HIV-infected people. While new diagnostic techniques 
are being developed and methods such as sputum induction 
have been shown to increase the yield of the sputum smear,15 
these are unavailable in most primary care settings in South 
Africa. It is often necessary to make a clinico-radiological 
diagnosis of smear-negative TB (SNTB) using an algorithm 
and to initiate empirical TB treatment while awaiting culture 
results. The sensitivity and specificity of clinical algorithms 
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Objectives. To evaluate the diagnostic accuracy of and reduction 
in diagnostic delay attributable to a clinical algorithm used 
for the diagnosis of smear-negative pulmonary tuberculosis 
(SNPTB) in HIV-infected adults. 
Design. An algorithm was designed to facilitate clinico-
radiological diagnosis of pulmonary TB (PTB) in HIV-infected 
smear-negative adult patients. A folder review was performed 
on the first 58 cases referred for empirical TB treatment using 
this algorithm.
Setting. Nolungile HIV Clinic, Site C, Khayelitsha.
Subjects. Subjects included 58 HIV-infected adult patients with 
suspected PTB consecutively referred to the local TB clinic 
for outpatient TB treatment using this algorithm between 12 
February 2004 and 30 April 2005. 
Outcome measures. Outcome measures were response of   
C-reactive protein, haemoglobin, weight and symptoms to TB 
treatment, and TB culture result. Diagnostic delay (in days) 
was calculated. 
Results. Thirty-two of the 58 patients (55%) had positive TB 
cultures (definite TB). Initiation of TB treatment occurred 
on average 19.5 days before the positive culture report. A 
further 21 patients (36%) demonstrated clinical improvement 
on empirical treatment (probable/possible TB). Two patients 
did not improve and subsequently died without a definitive 
diagnosis. Three patients defaulted treatment. 
Conclusions. SNPTB is more common in HIV-infected patients 
and leads to diagnostic delay. This algorithm allowed for 
earlier initiation of TB treatment in HIV-infected patients 
presenting with symptoms of PTB and negative smears or non-
productive cough in a high TB incidence setting. 
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used for the diagnosis of TB will vary depending on where 
they are implemented and will be influenced by local factors 
such as HIV prevalence, prevalence of conditions that mimic 
TB and the acumen of local clinicians. It is therefore necessary 
to validate an algorithm in a specific locality before widespread 
use.16 
This study aimed to validate one such algorithm in a 
primary care setting at the Nolungile HIV Clinic in Site C, 
Khayelitsha, which is a township on the outskirts of Cape 
Town with a population of approximately 400 000 people and 
a TB incidence rate of 1 612/100 000 in 2005 (Virginia Azevedo, 
Khayelitsha District Manager, City of Cape Town – personal 
communication). 
Methods
A smear-negative algorithm (Fig. 1) that could be used to 
initiate TB treatment empirically in HIV-infected adults 
with symptoms of PTB but negative sputum smears or non-
productive cough, was designed by doctors working in 
Khayelitsha in 2004. This algorithm was based on the World 
Health Organization (WHO) criteria17 and a study undertaken 
previously in Cape Town18 to validate case definitions for 
SNTB. The WHO diagnostic criteria for SNTB at the time were: 
at least 3 negative sputum smears, radiographic abnormalities 
consistent with active PTB, no response to a broad-spectrum 
antibiotic, and the decision by a clinician to treat with a full 
course of antituberculosis treatment.17 Patients were referred 
by an HIV clinician to the local TB clinic using this algorithmic 
approach from February 2004. 
All referred patients were clinically unwell and deteriorating 
but well enough to be treated (at least initially) as outpatients. 
Those with suspected TB who were too sick to be treated as 
outpatients were referred to a secondary hospital for admission 
and were not included in this analysis.
In order to increase specificity for the diagnosis of active 
TB and not overload the TB service, the following criteria had 
to be met before referral for empirical TB treatment: (i) cough 
with night sweats and/or weight loss for more than 2 weeks; 
Fig. 1. The smear-negative algorithm. (CXR = chest radiograph; FNAB = fine-needle aspiration biopsy; LN = lymph node; ADA = adenosine deaminase; 
MCS = microscopy, culture and sensitivity; AFB = acid-fast bacilli; RR = respiratory rate; PCP = pneumocystis pneumonia; CRP = C-reactive protein;  
Hb = haemoglobin.)
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MANAGEMENT OF HIV-POSITIVE TB SUSPECTS IN KHAYELITSHA:  PULMONARY PRESENTATION
Sputum smear x 2
FNAB of LN _> 2 cm for TB microscopy (+/- culture and cytology)
Amoxicillin 500mg tds x 7 days (or doxycycline if penicillin allergic)
Smear(s) positive 
or granulomas on 
FNAB*
TB TREATMENT 
Regimen 1 or 2
Symptoms 
and signs 
resolved, 
weight stable 
and smears 
negative
DISCHARGE
No sputum produced or smears negative 
and remains symptomatic
1) CXR
2) 3rd sputum for smear and 
culture (+/- blood for CRP)
START EMPIRICAL TB 
TREATMENT  if clinical picture and 
CXR consistent with active TB as 
decided by medical officer in HIV clinic
TB treatment monitoring:  CRP, Hb, 
weight, temperature, Karnofsky and 
symptoms 
CXR clear or not 
consistent with 
active TB
REFER TO 
SECONDARY 
HOSPITAL Favourable 
response
Poor response 
at 8 weeks (or 
earlier if 
deterioration)
Pleural effusion > 1/3 
hemithorax, tap to 
exclude empyema and 
send for protein, ADA, 
MCS and AFB/TB 
culture
Consider PCP if RR > 
30, cyanosed, ground 
glass bilateral 
infiltrate on CXR
Smear or 
culture 
positive
PULMONARY 
PRESENTATION =
Cough > 14 days and/or 
CXR infiltrate with or 
without night sweats, 
recent weight loss or 
deteriorating level of 
function
*If only one smear is 
positive then perform CXR 
and/or 3rd sputum for TB 
microscopy and culture for 
corroboration, but start TB 
treatment regardless
Sputum smear x 2
F  of  ≥ 2cm for TB microscopy (+/- culture and cytology)
Amoxicillin 500 mg tds x 7 days (or doxycycline if penicillin allergic)
1) CXR
2) 3rd sputum for smear and 
     culture (+/- blood for CRP)
 t t t it i : CRP, Hb, 
ei t, t score 
and sy ptoms
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(ii) inadequate clinical response to broad-spectrum antibiotics; 
(iii) deteriorating level of function; (iv) chest radiograph 
consistent with active PTB or miliary TB; (v) pleural fluid sent 
for adenosine deaminase (ADA) testing if effusion present; (vi) 
fine-needle aspiration biopsy (FNAB) of any peripheral lymph 
nodes > 2 cm in diameter if lymphadenopathy present.
Patients who were diagnosed with TB and referred for 
treatment on the basis of a positive smear from a FNAB 
were not included in this cohort. Once initiated on empirical 
TB treatment, patients were monitored every 2 - 3 weeks at 
the HIV clinic. Outcomes were assessed after 4 - 8 weeks 
of empirical TB treatment and were determined according 
to the following criteria: (i) symptom response; (ii) weight 
gain (or loss); (iii) serial C-reactive protein (CRP); (iv) serial 
haemoglobin; and (v) TB culture result from sputum, pleural 
fluid, or FNAB.
If there was a favourable clinical response to empirical 
TB treatment, then the patient received a full course of TB 
treatment regardless of the culture result. If there was a poor 
clinical response to empirical TB treatment, then the patient 
was referred to a secondary hospital for further management. 
A folder review was performed to assess the outcomes of 
patients referred using the algorithm between 12 February 2004 
and 30 April 2005. Approval for the study was granted by the 
University of Cape Town Research Ethics Committee.
Results
Fifty-eight patients were referred to the adjacent TB service 
using the algorithm. Four patients had 1 sputum sample that 
was ‘scanty positive’ for AFB, but they were included in the 
cohort because they would not have been eligible to start TB 
treatment according to the National TB Programme Protocol. 
The other 54 patients either could not produce sputum or had 
1 or more negative smears. Baseline data for the cohort are 
shown in Table I.
The outcomes of the 58 cases are shown in Fig. 2. Thirty-
two cases (55.2%, 95% confidence interval (CI): 42 - 68%) were 
diagnosed as having ‘definite’ TB on the basis of positive 
cultures for Mycobacterium tuberculosis (MTB). Twenty-four of 
these positive cultures were sputum specimens, 4 were pleural 
fluid specimens, 3 were lymph node aspirates, and 1 was from 
a chest abscess aspirate. 
Four of the 32 positive cultures were not from initial 
specimens; these cultures were positive on subsequent 
specimens done for various reasons. Two of these 4 patients 
defaulted TB treatment and had culture-positive sputum 
specimens when they returned after treatment interruption. 
The third case had a dry cough and initially improved 
after 8 weeks of empirical TB treatment, only to deteriorate 
subsequently; subsequent sputum culture and sensitivity 
showed multidrug-resistant (MDR) MTB. Initially the fourth 
case did not improve clinically on empirical TB medication, 
and subsequently developed a chest wall abscess. Needle 
aspiration of this abscess grew drug-sensitive MTB.
Sensitivity results from the 28 cases with initial cultures that 
were positive demonstrated an additional 2 cases of MDR TB. 
All 3 MDR cases had initial clinical improvement at 8 weeks of 
empirical TB medication, but deteriorated subsequently.
Five cases without positive cultures were classified as having 
‘probable’ TB, defined as clinical improvement after 8 weeks 
of TB treatment and a miliary pattern on chest radiograph or 
pleural effusion with an ADA level > 30 U/l. Four of these 
cases were unable to produce sputum specimens (Table II). 
Of the remaining 21 TB suspects, 16 had improved clinically 
at 4 - 8 weeks on treatment without proof of TB by positive 
culture and were regarded as ‘possible’ TB cases. Nine of 
these 16 cases were unable to produce a sputum specimen 
and therefore cultures were not done. The other 7 cases had 
negative sputum cultures but significant clinical improvement 
(weight gain and/or improvement in TB symptoms). Six of 
these 16 cases had follow-up CRP measurements, 4 of which 
showed lowering of CRP. In addition, 3 of the 16 cases had a 
documented rise in haemoglobin on empirical TB medication. 
The median weight gain in these 16 cases was 3.5 kg, which 
occurred over a median duration of 9 weeks of empirical TB 
treatment. Clinical details of these 16 ‘possible’ TB cases are 
summarised in Table III.
Two cases did not improve significantly after 8 weeks of 
TB treatment and required referral to a secondary hospital 
for further investigations. Both died without the cause of 
their illness or death being determined. The remaining 3 
patients defaulted TB treatment. Attempts were made to 
trace these patients. One patient, who had initially improved 
symptomatically with weight gain after 2 weeks of TB 
treatment and then defaulted, had died at a secondary hospital 
4 weeks later. Another patient defaulted TB medication and 
died 5 weeks later. The outcome of the third case could not be 
determined.
Analysis of the 28 cases confirmed to have active TB by 
positive culture on initial specimens showed that they were 
started on TB treatment a median 19.5 days before cultures 
became positive. The date used for the positive culture result 
was the date that the laboratory reported growth of acid-fast 
bacilli (AFB). In 1 of these 28 patients TB was also confirmed 
by a positive smear from a lymph node FNAB that became 
available after empirical TB treatment was commenced, but 
before the culture result. Subsequent identification showed M. 
tuberculosis in all patients with a positive culture result. 
The chest radiographs of 50 cases were reviewed after the 
study period by an experienced chest radiologist. Thirty-nine 
(78%) were assessed as being compatible with active PTB, 
whereas 11 (22%) were assessed as having no features of 
active TB: 7 were reported as normal or ‘virtually’ normal, 2 as 
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past PTB without evidence of active TB, 1 showed features 
suggestive of Kaposi’s sarcoma, and 1 had smoking-related 
changes. Of the 11 assessed to have no features of active TB, 
5 had positive TB cultures and improved on TB treatment 
(including the 1 with features suggestive of Kaposi’s), 3 had 
‘possible TB’, 2 defaulted, and 1 deteriorated and died.
Discussion
Traditionally, the TB programme in Khayelitsha and other 
parts of South Africa has required patients to have 2 positive 
smears, 1 positive culture, or a referral from a secondary 
or tertiary hospital before TB treatment would be initiated. 
Clinicians working in Khayelitsha found that difficulty 
making the diagnosis of TB in HIV-infected people when 
following these protocols led to delays in the initiation 
of TB treatment, with consequent clinical deterioration, 
hospitalisation and mortality. The algorithmic approach was 
developed to address this.
Of the 58 patients commenced on TB treatment using this 
algorithm, 55% had ‘definite’ TB and 36% had ‘probable’ 
or ‘possible’ TB. It is possible that some in the ‘possible’ 
category may have had bacterial chest infections that 
responded to rifampicin, but the approach of giving an 
antibiotic before empirical TB treatment was intended to 
minimise this. A total of 91% of patients (53/58) commenced 
on empirical TB treatment based on a clinico-radiological 
diagnosis therefore showed a response to therapy. Diagnostic 
delay was also reduced. In those patients who eventually 
had positive TB cultures, the TB treatment was initiated 
almost 3 weeks before the culture result was available. If 
logistical factors are taken into account such as the time it 
takes to receive the laboratory report and recall the patient, 
the delay would have been even longer. A further 21 patients 
who responded to TB treatment were culture-negative or 
Table I. Baseline data for the 58 smear-negative patients
Characteristic                    Value 
Study participants  (N)                        58
Age (years)        
Median                   32.5    
Interquartile range                                          28.0 - 36.8
Female sex (N (%))                       37 (64)
WHO clinical stages before TB diagnosis (N (%))
Stage 2                6 (10)         
Stage 3                33 (57)
Stage 4               19 (33)
CD4 cell count (cells/µl)
Median                119 
Interquartile range              71 - 196
Antiretroviral treatment exposure (N (%))
Before starting empirical TB            13 (22)
Started during first 8 weeks of TB treatment            2 (3)
Prior TB episodes (N (%))
None                 28 (48)
One                18 (31)
Two                 7 (12)
Three                3 (5)
Unknown               2 (3) 
Symptoms and signs at time of initial designation 
as a TB suspect
Cough duration (days)
Median                  14
Interquartile range               7 - 28
Weight loss (kg)
Median                  4.2
Interquartile range                2.7 - 6.5 
Weight loss duration (weeks)
Median                    7
Interquartile range              4 - 17
Interval from time of designation as TB suspect 
to initiation of empirical TB medication
Weight loss during this period (kg)
Median                  0.9
Interquartile range                 0.0 - 2.0
Duration (days)
Median                    7 
Interquartile range               4 - 15
Antibiotics before starting empirical TB medication 
(N (%))
One course                   23 (40)
Two or more courses                  35 (60)
Amoxicillin                   42 (72)
Doxycycline                   20 (34)
Erythromycin                  16 (28)
Ciprofloxacin                     8 (14)
Cotrimoxazole                        4 (7)
Co-amoxyclavulanic acid               2 (3)
Metronidazole               1 (2)
Flucloxacillin                2 (3)
Smear results (N (%))
No sputum due to dry cough                19 (33)
One scanty positive sputum smear                    4 (7)
One negative sputum smear                12 (21)
Two or more negative smears                 23 (40)
Chest X-ray interpretations by HIV clinician (N)
Miliary pattern                      7 (12)
Other infiltrates                   16 (28)
Pleural effusion/thickening                 16 (28)
Table I. Baseline data for the 58 smear-negative patients 
(continued)
Characteristic              Value
Adenopathy                   11 (19)
Infiltrate and adenopathy                       5 (9)
Pleural effusion/thickening and infiltrates             2 (3)
Pleural effusion and adenopathy              1 (2)
Haematological and chemistry results (N)
Initial haemoglobin (g/dl, N = 54)
Mean                    9.9      
Standard deviation                        2.3
Follow-up haemoglobin (g/dl, N = 20)
Mean                  10.8
Standard deviation                        1.8 
Initial C-reactive protein (mg/dl, N = 49)
Mean                   110
Standard deviation                  65
Follow-up C-reactive protein (mg/dl, N = 10)
Mean                           47
Standard deviation                          32
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unable to produce sputum and may potentially have had even 
longer diagnostic delay. 
In our cohort TB was confirmed by culture in 55% of cases. 
This is higher than the rates reported in other African cohorts 
of smear-negative TB suspects. Hargreaves et al.19 reported 
that TB was confirmed in 39% of patients referred for TB 
treatment with a diagnosis of SNTB in Malawi. The study 
done by Wilson et al.18 in Cape Town reported higher rates 
of confirmed TB than in our study. They used a set of case 
definitions to diagnose smear-negative TB at a referral hospital. 
Of the patients in that study who fulfilled the pulmonary 
infiltrate case definition, 77% had confirmed TB by culture 
Fig. 2.  Outcomes of 58 consecutive adult cases referred for TB treatment using the smear-negative algorithm by an HIV clinician in a high-incidence TB 
setting. (*Four of these smear-negative cases had ‘scanty positive’ sputum results; †A positive culture was considered to be ‘definite TB’; ‡Case definition of 
‘probable TB’:  clinical improvement after 8 weeks of TB treatment, PLUS miliary pattern on chest radiograph OR pleural effusion with high ADA level;  
§Case definition of ‘possible TB’:  clinical improvement after 8 weeks of TB treatment, with or without significant lowering of CRP after 2 weeks; ¶‘Clinical 
improvement’ is defined as weight gain and/or improvement in TB symptoms.)
25
58 adult TB suspects 
without positive smears 
(smears negative*
or no sputum sent  
because of dry cough) 
32 definite 
TB+ cases 
proven by 
culture 
5 probable TB cases (3 
had miliary patterns on 
CXR, and 2 had high ADA 
levels in pleural effusion, all 
with clinical improvement)
(see Table II) 
3 cases defaulted TB treatment:
- two died 
- one could not be traced 
2 cases did not improve
on empirical TB medication 
by 8 weeks and required 
referral to secondary hospital 
(both died without cause of 
death being determined) 
53 cases improved
on empirical TB 
medication  
over 8 weeks 
16 possible TB§ cases 
who showed clinical 
improvement  over 8 weeks 
of empirical TB medication 
(see Table III) 
†
Table II. Outcomes of five cases with probable tuberculosis 
       
Patient  CXR findings  Clinical improvement on empirical TB treatment  Other findings
    1  Pleural effusion  Yes, with 2.4 kg weight gain at 10 weeks  High ADA* ( 63 U/l)
    2  Pleural effusion  Cough improved, but 6.2 kg weight loss at 8 weeks  High ADA (70 U/l)
     (had vomiting with TB medication)
    3  Miliary pattern  Yes, with 10.7 kg weight gain at 4 months  CRP 125 → 37 mg/dl
    4  Miliary pattern  Symptoms improved at 2 weeks, then patient moved
     to Eastern Cape 
    5  Miliary pattern  Symptoms improved; 0.1 kg weight gain at 7 weeks Hb 6.7 → 10.3 g/dl
*Values > 30 U/l are suggestive of TB, but ADA is also raised in parapneumonic and malignant effusions.
CXR = chest radiograph; ADA = adenosine deaminase; CRP = C-reactive protein; Hb = haemoglobin. 
5 probable TB‡ cases (3 
had military patterns on 
CXR, and 2 had high ADA 
levels in pleural effusion, all 
with cli ical improvement¶) 
(see Table II)
16 possible TB§ cases 
who s wed clinical 
i prove ent¶ over 8 
weeks of empirical TB 
medication (see Table III)
 cases defaulted TB treatment: 
•  two died
•  one could not be
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or histological analysis and 14% had possible TB, having had 
a response to empirical TB treatment. This gave a positive 
predictive value of 92% for this case definition. Although the 
proportion of patients responding to TB treatment was very 
similar to that in our study, the culture-positive rate was higher 
than in our study, probably because multiple cultures were 
done from different sites and sputum induction was used. Our 
study site reflects the clinical situation in a busy primary health 
care clinic where the quality of samples could not be assured; 
in some patients sputum could not be obtained and sputum 
induction was unavailable. 
The algorithm was designed to encourage the consideration 
of alternative diagnoses at initial presentation. This process 
included the consideration of pneumocystis pneumonia 
in distressed patients, aspiration of pleural effusions to 
inspect for purulent effusions (empyema) and bloody 
effusions (suggestive of Kaposi’s sarcoma) and a course 
of a broad-spectrum antibiotic to treat bacterial infections. 
Three patients in this cohort were found to have MDR TB 
when they deteriorated after an initial improvement on TB 
treatment, making it an important consideration in patients 
not improving on empirical TB treatment. The 2 patients who 
deteriorated despite being on TB treatment with negative 
cultures died without a definitive diagnosis being made. In 
general, HIV-infected patients not improving on empirical TB 
treatment should be investigated for MDR TB, non-tuberculous 
mycobacterial infection, systemic fungal infections, lymphoma, 
Kaposi’s sarcoma and nocardiosis.16 Ciprofloxacin was used 
in 8 of the TB suspects in this study. However this is not an 
advisable antibiotic to use in TB suspects as the antituberculous 
activity of the fluoroquinolones may cause a temporary 
improvement in TB symptoms, thereby lengthening diagnostic 
delay, and predispose to MTB fluoroquinolone resistance.20,21  
A chest radiograph ‘consistent with active TB’ was one of 
the criteria required in this algorithm before empirical TB 
medication could be initiated. Features on the chest radiograph 
that could suggest active TB include miliary pattern, 
lymphadenopathy, pleural effusion or nodular infiltrates. 
However, the HIV clinician’s interpretations of the radiographs 
did not always correlate with the subsequent radiologist’s 
interpretations. The HIV clinician regarded all the radiographs 
as compatible with active TB, but the radiologist reported 
that 22% of radiographs were not consistent with active TB. 
Seventy-three per cent of this latter group were subsequently 
found to have ‘definite’ or ‘possible’ TB.  Other studies12 
have also found that up to 19% of patients with sputum 
culture-positive TB may have normal chest radiographs, and 
thus it may be feasible to remove the requirement for the 
chest radiograph to be compatible with active TB from this 
algorithm. 
Many areas in southern Africa have high TB-HIV co-infection 
rates, but limited access to radiographs, cultures and doctors. 
Ta
bl
e 
II
I.
 O
ut
co
m
es
 o
f 
16
 c
as
es
 w
it
h 
po
ss
ib
le
 tu
be
rc
ul
os
is
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
   
   
   
   
   
   
  I
m
pr
ov
em
en
ts
 in
Pa
ti
en
t  
   
   
   
 
Sp
ec
im
en
 s
en
t f
or
 c
ul
tu
re
? 
   
   
   
   
   
 W
ei
gh
t r
es
po
ns
e 
   
 
   
   
   
   
   
  C
ou
gh
   
   
N
ig
ht
 s
w
ea
ts
   
 A
pp
et
it
e 
   
   
C
he
st
 p
ai
n 
 
L
ab
or
at
or
y 
re
su
lt
s 
af
te
r 
st
ar
ti
ng
 T
B
 m
ed
ic
at
io
n
   
 1
 
   
   
   
   
   
Ye
s 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
3.
4 
kg
 in
cr
ea
se
 o
ve
r 
2 
m
on
th
s 
  
√ 
 
√ 
√ 
 
 
C
R
P 
90
 →
 2
7 
m
g/
d
l a
ft
er
 2
 w
ee
ks
   
 2
 
   
   
   
   
   
Ye
s 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
3.
5 
kg
 in
cr
ea
se
 o
ve
r 
10
 w
ee
ks
 
√ 
√ 
√ 
 
 
C
R
P 
50
 →
 2
4 
m
g/
d
l a
ft
er
 3
 w
ee
ks
   
 3
 
   
   
   
N
o 
(d
ry
 c
ou
gh
) 
   
   
   
   
   
   
   
   
   
   
   
   
   
 5
 k
g 
in
cr
ea
se
 o
ve
r 
2 
m
on
th
s 
√ 
√ 
√ 
 
 
–
   
 4
 
   
   
   
N
o 
(d
ry
 c
ou
gh
) 
   
   
   
   
   
   
   
   
   
   
   
   
   
 3
.2
 k
g 
in
cr
ea
se
 o
ve
r 
2 
m
on
th
s 
√ 
 
 
√ 
 
–
   
 5
 
   
   
   
   
   
 
N
o 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
0.
4 
kg
 in
cr
ea
se
 o
ve
r 
7 
w
ee
ks
  
√ 
√ 
 
 
 
C
R
P 
10
4 
→
 9
8 
m
g/
d
l a
ft
er
 2
 w
ee
ks
   
 6
 
   
   
  
Ye
s 
(2
 x
 n
eg
at
iv
e)
   
   
   
   
   
   
   
   
   
   
   
   
  2
.3
 k
g 
in
cr
ea
se
 o
ve
r 
10
 w
ee
ks
  
√ 
 
 
 
 
–
   
 7
 
   
   
  
Ye
s 
(2
 x
 n
eg
at
iv
e)
   
   
   
   
   
   
   
   
   
   
   
   
  3
.6
 k
g 
in
cr
ea
se
 a
ft
er
 1
1 
w
ee
ks
 
√ 
√ 
 
 
 
C
R
P 
42
 →
 3
5 
m
g/
d
l a
ft
er
 2
 w
ee
ks
   
 8
 
   
   
Ye
s 
(1
 x
 n
eg
at
iv
e)
   
   
   
   
   
   
   
   
   
   
   
   
  N
ot
 w
ei
gh
ed
 d
ue
 to
 p
er
ip
he
ra
l 
 
 
 
 
 
 
 
 
 
 
ne
ur
op
at
hy
 
 
 
√ 
 
 
 
 
–
   
 9
 
   
   
  
N
o 
(d
ry
 c
ou
gh
) 
   
   
   
   
   
   
   
   
   
   
   
   
   
4.
2 
kg
 in
cr
ea
se
 a
ft
er
 3
.5
 m
on
th
s 
√ 
 
 
√ 
 
–
   
 1
0 
   
   
   
N
o 
(d
ry
 c
ou
gh
) 
   
   
   
   
   
   
   
   
   
   
   
   
   
3.
0 
kg
 in
cr
ea
se
 a
ft
er
 2
 m
on
th
s 
√ 
√ 
√
   
 1
1 
   
N
o 
(n
o 
co
ug
h)
, F
N
A
B
 n
ot
 d
ia
gn
os
ti
c 
   
   6
.3
 k
g 
in
cr
ea
se
 a
ft
er
 1
0 
w
ee
ks
 
 
√ 
√ 
 
 
–
   
 1
2 
   
   
   
   
   
  
N
o 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
  
7.
3 
kg
 in
cr
ea
se
 o
ve
r 
3.
5 
m
on
th
s 
√ 
√ 
√ 
 
 
–
   
 1
3 
   
   
   
N
o 
(d
ry
 c
ou
gh
) 
   
   
   
   
   
   
   
   
   
7.
2 
kg
 in
cr
ea
se
 o
ve
r 
2 
m
on
th
s 
√ 
√ 
 
 
 
H
b 
8.
7 
→
 1
1.
7 
g/
d
l a
ft
er
 3
 m
on
th
s
   
 1
4 
   
   
   
   
   
 
Ye
s 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
4.
9 
kg
 in
cr
ea
se
 o
ve
r 
2 
m
on
th
s 
 
√ 
√ 
   
 
 
 
C
R
P 
91
 →
 1
5 
m
g/
d
l, 
H
b 
6.
9 
→
 8
.4
 g
/
d
l a
ft
er
 1
0 
w
ee
ks
   
 1
5 
   
   
   
   
   
  
N
o 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
0.
7 
kg
 in
cr
ea
se
 o
ve
r 
2 
m
on
th
s 
√ 
√ 
 
 
 
C
R
P 
17
5 
→
 1
2 
m
g/
d
l a
ft
er
 6
 w
ee
ks
, H
b 
5.
5 
→
 1
0.
6 
g/
d
l a
ft
er
 3
 m
on
th
s
   
 1
6 
   
   
   
Ye
s 
(1
 x
 n
eg
at
iv
e)
   
   
   
   
   
   
  
3.
1 
kg
 in
cr
ea
se
 o
ve
r 
10
 w
ee
ks
 
√ 
√ 
 
 
 
–
C
R
P 
=
 C
-r
ea
ct
iv
e 
pr
ot
ei
n,
 H
b 
=
 h
ae
m
og
lo
bi
n;
 F
N
A
B
 =
 f
in
e-
ne
ed
le
 a
sp
ir
at
io
n 
bi
op
sy
.
Pg 517-523.indd   522 6/20/07   8:14:59 AM
ORIGINAL ARTICLES
523
July 2007, Vol. 97, No. 7  SAMJ
If this smear-negative algorithm was modified to exclude chest 
radiographs, it could be used in such rural settings.  A nurse 
could use clinical symptoms, Karnofsky performance score, 
lack of response to broad-spectrum antibiotics and CRP (if 
available) to initiate and monitor empirical TB therapy.  Any 
such algorithm would first have to be validated.
Conclusions
The smear-negative algorithm allowed for earlier initiation of 
TB treatment in HIV-infected adults presenting with symptoms 
of PTB in a high TB incidence setting. This algorithm should 
be validated and could be modified for use by nurses in rural 
areas where doctors and chest radiographs are not readily 
available. Such algorithms could be used in the National TB 
Programme to reduce diagnostic delay associated with SNTB 
in HIV-infected patients in South Africa. 
The authors wish to acknowledge Professor H Goodman, 
who reviewed the chest radiographs.
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